Eloxx Pharmaceuticals, Inc.

Eloxx reported fourth-quarter 2020 net loss of $6.1 million, or $0.15 per share, versus a net loss of $11.6 million, or $0.29 per share in the same quarter of 2019. Fourth-quarter R&D expense was $2.6 million versus $5.9 million a year ago, and G&A expense was $3.1 million versus $5.6 million. For the full year 2020, net loss was $34.6 million, or $0.86 per share, compared with a net loss of $50.9 million, or $1.34 per share in 2019. Full-year R&D expense was $14.6 million versus $26.3 million, and G&A expense was $14.8 million versus $24.2 million. Cash and cash equivalents were $24.7 million at December 31, 2020, which management said should fund operations through top-line CF data and into the fourth quarter of 2021. Forward guidance: top-line ELX-02 CF data is expected in the first half of 2021.

Greg Williams emphasized that Eloxx is continuing to advance its ERSG library, but the immediate focus is completing the Phase II ELX-02 cystic fibrosis trials. He repeatedly framed the first-half 2021 data as a potential “major value inflection point” and said the company is “laser focused” on the program. His tone was optimistic but measured, pointing to safety progress, higher-dose escalation, new trial sites, orphan designation, and growing scientific interest as indicators of momentum.

Stephen MacDonald said Eloxx ended 2020 with $24.7 million in cash and cash equivalents, and management believes that cash should fund operations through the CF topline readout and into the fourth quarter of 2021. He highlighted a narrower quarterly and annual net loss, with reduced operating expenses driven mainly by lower headcount, salaries, clinical and preclinical research costs, and professional services. He also noted non-cash stock compensation of $1.3 million in the fourth quarter and $8.7 million for the full year, plus 40.157 million common shares outstanding at year-end.

Analysts focused on what would constitute success in CF and what the topline package will include. Greg Williams said a meaningful result would look like Orkambi- or Symdeko-like sweat chloride reductions, roughly in the five-millimole-per-liter range or better, and noted literature suggests sweat chloride can vary by about eight or nine millimoles per liter day to day, so sufficient patient numbers matter. He said the company has not yet disclosed exact enrollment or the full contents of the topline release, but plans to pool data across Europe, Israel, Australia, the U.S. and Canada, and expects a clearer dose response across the four doses being tested.